# A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

> **NCT07122193** · PHASE3 · RECRUITING · sponsor: **Merz North America, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Neuromuscular Agents
- Peripheral Nervous System Agents
- Physiological Effects of Drugs
- Acetylcholine Release Inhibitors
- Membrane Transport Modulators
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Neurotransmitter Agents
- incobotulinumtoxinA
- Botulinum Toxins, Type A

## Interventions

- **DRUG:** NT 201
- **DRUG:** NT 201 Placebo

## Key facts

- **NCT ID:** NCT07122193
- **Lead sponsor:** Merz North America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2026-10
- **Final completion:** 2028-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07122193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07122193, "A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07122193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*